These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34749893)

  • 1. Obesity and Nonalcoholic Fatty Liver Disease.
    Chaney A
    Nurs Clin North Am; 2021 Dec; 56(4):543-552. PubMed ID: 34749893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paediatric non-alcoholic fatty liver disease: an overview.
    AlKhater SA
    Obes Rev; 2015 May; 16(5):393-405. PubMed ID: 25753407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
    Pydyn N; Miękus K; Jura J; Kotlinowski J
    Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.
    Assunção SNF; Sorte NCB; Alves CD; Mendes PSA; Alves CRB; Silva LR
    Nutr Hosp; 2017 Jun; 34(3):727-730. PubMed ID: 28627213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New aspects of nonalcoholic steatohepatitis].
    Stefan N
    Internist (Berl); 2019 Feb; 60(2):128-132. PubMed ID: 30645665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.
    Hardy T; Oakley F; Anstee QM; Day CP
    Annu Rev Pathol; 2016 May; 11():451-96. PubMed ID: 26980160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
    Roeb E; Geier A
    Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
    Mathews SE; Kumar RB; Shukla AP
    Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2010 Nov; 16(42):5280-5. PubMed ID: 21072890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease.
    Allard J; Le Guillou D; Begriche K; Fromenty B
    Adv Pharmacol; 2019; 85():75-107. PubMed ID: 31307592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-drug approaches to NASH: what's in the development pipeline?
    Johnston MP; Patel J; Byrne CD
    Expert Opin Investig Drugs; 2020 Feb; 29(2):143-150. PubMed ID: 31524533
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.
    Brea Á; Pintó X; Ascaso JF; Blasco M; Díaz Á; González-Santos P; Hernández Mijares A; Mantilla T; Millán J; Pedro-Botet J;
    Clin Investig Arterioscler; 2017; 29(3):141-148. PubMed ID: 27692633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
    Gottlieb A; Mosthael W; Sowa JP; Canbay A
    Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of diet and lifestyle changes in nonalcoholic fatty liver disease.
    Nseir W; Hellou E; Assy N
    World J Gastroenterol; 2014 Jul; 20(28):9338-44. PubMed ID: 25071328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.